Incyte Corporation
NASDAQ:INCYBiotechnology
-$0.77 today
- Market cap
- $24.01B
- Beta
- 0.79
- P/E (TTM)
- 13.7
- EPS (TTM)
- $7.18
Volume 1.21M
Average 1.58M
INCY Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Incyte CorporationNASDAQ: INCY
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin widens to 41.7%
Operating margin was 41.7% in Q2 FY2026, up 16.1 pp from a year earlier. On a trailing-twelve-month basis it was 31.6%, up 10.4 pp year over year. Over 3 fiscal years it widened by 8.7 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 17 analysts of 17.9% for the fiscal year ending Dec 2026, down from 26.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 41.7%+16.2 pp QoQ
- Last fiscal yearDec 2025
- 26.1%+23.7 pp YoY
- LTMJun 2026
- 31.6%+10.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 26.1%
- Year-over-year change
- +23.7pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.1% | +23.7pp |
| FY2024 | 2024-12-31 | 2.4% | -15.3pp |
| FY2023 | 2023-12-31 | 17.7% | +0.3pp |
| FY2022 | 2022-12-31 | 17.4% | -2.2pp |
| FY2021 | 2021-12-31 | 19.6% | — |
Operating Margin vs competitors
How INCY compares with its peers on the latest reported figures
- INCY's LTM Jun 2026 operating margin of 31.6% is the 5th highest of the 8 companies compared; the peer median is 32.3%.
- Its year-over-year change of +10.4 pp is the 5th highest of 7, against a peer median of +38.2 pp.
- Over three fiscal years its change of +8.7 pp compares with a peer median of +25.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 41.3% | +360.6 pp | +135.8 pp | |
| LTM Jul 2026 | 39.9% | +8.5 pp | +25.1 pp | |
| LTM Jun 2026 | 34.7% | +53.0 pp | +16.1 pp | |
| LTM Jun 2026 | 32.3% | — | -9.6 pp | |
| LTM Jun 2026 | 31.6% | +10.4 pp | +8.7 pp | |
| LTM Jun 2026 | 25.6% | -1.5 pp | -19.3 pp | |
| LTM Sep 2026 | 2.5% | +23.5 pp | +376.1 pp | |
| LTM Mar 2026 | -344.6% | +966.2 pp | +2259.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding INCY) | 32.3% | +38.2 pp | +25.1 pp | |
Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.99B | 3.39B | 3.7B | 4.24B | 5.14B |
| Cost of Revenue | 150.99M | 207M | 254.99M | 312.1M | 372.1M |
| Gross Profit | 2.84B | 3.19B | 3.44B | 3.93B | 4.77B |
| Gross Margin | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% |
| Research & Development | 1.46B | 1.59B | 1.63B | 2.61B | 2.05B |
| Selling, General & Admin | 739.56M | 1B | 1.16B | 1.22B | 1.38B |
| Operating Expenses | 2.25B | 2.6B | 2.79B | 3.83B | 3.43B |
| Depreciation & Amortization | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M |
| EBITDA | 630.2M | 599.64M | 919.43M | 408.16M | 1.76B |
| EBITDA Margin | 21.1% | 17.7% | 24.9% | 9.6% | 34.2% |
| Operating Income | 585.78M | 591.63M | 655.36M | 101.29M | 1.34B |
| Operating Margin | 19.6% | 17.4% | 17.7% | 2.4% | 26.1% |
| Interest Income | 0 | 0 | 0 | 128.71M | 105.6M |
| Interest Expense | 1.91M | 2.67M | 2.55M | 2.28M | 2.43M |
| Other Income / Expenses | (15.33M) | (62.51M) | 178.86M | 215.34M | 321.66M |
| Income Before Tax | 570.44M | 529.12M | 834.22M | 316.63M | 1.66B |
| Pre-Tax Margin | 19.1% | 15.6% | 22.6% | 7.5% | 32.4% |
| Income Tax Expense | (378.14M) | 188.46M | 236.62M | 284.02M | 377.8M |
| Net Income | 948.58M | 340.66M | 597.6M | 32.62M | 1.29B |
| Net Margin | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| EPS (Basic) | 4.30 | 1.53 | 2.67 | 0.16 | 6.59 |
| EPS (Diluted) | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 |
| Weighted Avg Shares | 220.43M | 222M | 223.63M | 207.11M | 195.2M |
| Weighted Avg Shares (Diluted) | 222.07M | 223.96M | 225.93M | 210.53M | 200.7M |
Incyte Corporation
NASDAQ:INCY
Intrinsic Alpha fair value
Locked
Current Price
$117.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.